Learn everything you need to know about Pitavastatin-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, ...
Among people living with HIV receiving antiretroviral therapy, those taking 4-mg pitavastatin daily were 35% less likely than those taking placebo to experience a major cardiovascular event over 5 ...
According to the authors, these improvements may be part of the reason why there was a lower rate of major adverse cardiovascular events in the REPRIEVE study. For people with HIV (PWH) who have a low ...
A new study published in AIDs Research and Therapy observed the association of using this specific statin on dyslipidemia in people living with HIV. The study was conducted as a randomized, ...
Clin Lipidology. 2010;5(3):309-323. One of these studies demonstrated that pitavastatin was non-inferior to atorvastatin at reducing LDL-C concentrations. [42] The study enrolled 821 patients with ...
Please provide your email address to receive an email when new articles are posted on . In patients with HIV at low to moderate CVD risk, pitavastatin lowered noncalcified plaque volume and reduced ...
First-ever meta-analysis of pitavastatin confirms no significant adverse effect compared with placebo or other statins on fasting blood glucose, HbA1c, or new-onset diabetes MONTGOMERY, Ala., Kowa ...
Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and HER2 receptors and thus relying primarily on cytotoxic chemotherapy.
Announcing a new article publication for Cardiovascular Innovations and Applications journal. According to the findings of randomized controlled trials, blood lipid levels in patients with coronary ...
PREVAIL U.S. primary and secondary lipid endpoints and lipoprotein particle analysis presented at the National Lipid Association Scientific Sessions SCOTTSDALE, Ariz., May 31, 2012 /PRNewswire via ...
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Pitavastatin Market- (By Type (1 mg, 2 mg and 5 mg), By Product Type (Tablets, Capsules and Oral ...
Clin Lipidology. 2010;5(3):309-323. Against this background, a non-inferiority study compared once-daily pitavastatin and pravastatin (1 vs 10 mg; 2 vs 20 mg; and 4 vs 40 mg) over 12 weeks in 942 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results